Európska únia - lotyština - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple mieloma - antineoplastiski līdzekļi - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Lotyšsko - lotyština - Zāļu valsts aģentūra

tarchomin pharmaceutical works "polfa" s.a., poland - bortezomibs - pulveris injekciju šķīduma pagatavošanai - 3,5 mg

Európska únia - lotyština - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastiski līdzekļi - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.